Stephens Cuts Phreesia (NYSE:PHR) Price Target to $20.00

Phreesia (NYSE:PHR) had its price objective reduced by Stephens from $32.00 to $20.00 in a research note published on Tuesday morning,Benzinga reports. They currently have an overweight rating on the stock.

Several other research analysts have also recently issued reports on the company. Mizuho reduced their price objective on Phreesia from $22.00 to $19.00 and set an “outperform” rating for the company in a research note on Tuesday, March 24th. Wells Fargo & Company cut their price target on shares of Phreesia from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Thursday, March 26th. Wall Street Zen lowered shares of Phreesia from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 8th. JPMorgan Chase & Co. restated a “neutral” rating and set a $16.00 price objective (down from $24.00) on shares of Phreesia in a research note on Tuesday. Finally, Needham & Company LLC dropped their price objective on shares of Phreesia from $35.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday. Twelve research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.00.

Phreesia Price Performance

NYSE PHR opened at $8.35 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.44 and a quick ratio of 2.44. The stock’s fifty day moving average price is $12.07 and its 200 day moving average price is $17.44. Phreesia has a 1 year low of $7.77 and a 1 year high of $32.76. The company has a market cap of $503.18 million, a price-to-earnings ratio of 278.20 and a beta of 0.86.

Phreesia (NYSE:PHR) last issued its earnings results on Monday, March 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). Phreesia had a return on equity of 3.33% and a net margin of 0.48%.The firm had revenue of $127.07 million during the quarter, compared to analysts’ expectations of $126.75 million. During the same quarter last year, the business earned ($0.11) EPS. The business’s revenue was up 15.9% on a year-over-year basis. As a group, equities research analysts forecast that Phreesia will post -1.1 earnings per share for the current year.

Insider Activity

In other Phreesia news, insider David Linetsky sold 6,038 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $16.36, for a total value of $98,781.68. Following the completion of the transaction, the insider directly owned 223,942 shares of the company’s stock, valued at approximately $3,663,691.12. The trade was a 2.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Evan Roberts sold 6,268 shares of the company’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $16.36, for a total value of $102,544.48. Following the completion of the sale, the insider owned 826,554 shares in the company, valued at approximately $13,522,423.44. This represents a 0.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 70,358 shares of company stock valued at $1,123,569 over the last 90 days. Company insiders own 5.50% of the company’s stock.

Institutional Trading of Phreesia

A number of hedge funds have recently added to or reduced their stakes in PHR. Granahan Investment Management LLC grew its position in Phreesia by 73.8% during the fourth quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company’s stock valued at $40,601,000 after buying an additional 1,018,987 shares during the period. Prosight Management LP acquired a new position in shares of Phreesia in the fourth quarter worth about $16,533,000. Millennium Management LLC boosted its stake in shares of Phreesia by 730.7% during the 3rd quarter. Millennium Management LLC now owns 1,064,132 shares of the company’s stock worth $25,028,000 after acquiring an additional 936,033 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Phreesia during the 4th quarter worth about $15,213,000. Finally, Greenhouse Funds LLLP grew its position in shares of Phreesia by 16.8% during the 3rd quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock valued at $91,317,000 after acquiring an additional 557,265 shares during the period. 92.10% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Analyst take: a MarketBeat piece argues Phreesia may have hit a trough and is well‑positioned to regain growth and market share over time, suggesting upside if execution and demand stabilize. Phreesia Hits Bottom in Q1: Rebound Ahead, Timing Uncertain
• Neutral Sentiment: Several large firms have issued neutral/market‑perform ratings (Robert W. Baird, JPMorgan, Citigroup), signaling limited near‑term conviction rather than outright sell ratings. Phreesia (NYSE:PHR) Earns “Neutral” Rating from Robert W. Baird
• Neutral Sentiment: Citizens JMP reaffirmed a market‑perform view, reflecting tepid near‑term expectations from another sell‑side firm. Citizens JMP Market Perform Reaffirmed
• Neutral Sentiment: Investor comparison coverage contrasts Phreesia with peers (MSP Recovery), providing context but not a clear directional trigger. Phreesia and MSP Recovery Critical Contrast
• Negative Sentiment: Primary catalyst: Phreesia reported its first full‑year profit but issued lower FY2027 revenue guidance, prompting a sharp selloff as investors focused on the reduced top‑line outlook. Phreesia (PHR) Is Down 25.5% After First Full-Year Profit But Lower 2027 Revenue Guidance
• Negative Sentiment: Multiple analysts cut expectations and targets (Canaccord cut its price target to $22; Needham, Stephens and BMO issued more pessimistic views), increasing selling pressure and lowering implied valuation. Needham Lowers Expectations for Phreesia BMO Capital Markets Issues Pessimistic Forecast for Phreesia Needham & Company LLC Has Lowered Expectations for Phreesia
• Negative Sentiment: The stock hit a new one‑year low after the earnings/guide miss, a technical signal that can accelerate outflows from momentum and quant funds. Phreesia Reaches New 1-Year Low After Earnings Miss
• Negative Sentiment: Legal risk: a law firm announced an investigation into potential securities‑law violations tied to prior guidance comments, adding uncertainty and potential headline risk. Investors in Phreesia Warned of Potential Securities Fraud
• Negative Sentiment: Some outlets and analysts pulled recommendations or expressed disappointment in growth guidance, reinforcing negative sentiment. Phreesia’s growth guidance disappointed. We’re pulling our recommendation.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.